Sartorius (SRT) AGM 2026 summary

Opening remarks and agenda

• AGM opened by the Supervisory Board Chairman, welcoming shareholders, proxies, and media, emphasizing the benefits of the virtual format for international participation.

• Meeting convened in accordance with legal requirements, with all necessary documents and notifications provided in advance.

• Details on participation, voting, and speaking rights explained, including use of the AGM portal for electronic engagement.

• Attendance at the AGM represented 25.45% of capital, with detailed breakdowns of shares and voting rights.

Board and executive committee updates

• Dr. Michael Grosse appointed CEO as of July 1, 2025, succeeding the long-standing CEO.

• Changes to the Supervisory Board included the resignation of two members and the appointment of two new employee representatives.

• Dietmar Müller elected as new Deputy Chairman of the Supervisory Board.

Financial performance review

• 2025 saw 7.6% revenue growth (constant currencies), reaching EUR 3.5 billion, and operating profit up 11.2% to over EUR 1 billion.

• Operating EBITDA margin increased by 1.7 percentage points to 29.7%.

• Bioprocess division achieved nearly double-digit growth; laboratory division returned to growth in H2 2025.

• Consumables business was the main driver of revenue and profitability.